<DOC>
	<DOCNO>NCT00473434</DOCNO>
	<brief_summary>The purpose trial evaluate dose distribution , effectiveness safety patient schizophrenia switched oral atypical antipsychotic Paliperidone ER . In study patient physician know name dose study drug . Newly diagnose patient also include study . In general , recommend Paliperidone ER dose 6 mg daily , however patient may require high low initial dose recommend range 3 12 mg daily . The dose adjust point study , maximum dose 12mg/day . Flexible dose chosen best mimic actual clinical practice.The safety assessment conduct throughout study include regular monitoring record Adverse Events Serious Adverse Events .</brief_summary>
	<brief_title>An Open Label Multicentre Study Determine Dose Distribution Paliperidone ER Patients With Schizophrenia</brief_title>
	<detailed_description>This trial non-randomised ( patient physician know study drug ) , single arm , open label multicentre study aim evaluate dose distribution , efficacy safety patient schizophrenia switched oral atypical antipsychotic Paliperidone ER . Newly diagnose patient also include study . In general , recommend Paliperidone ER dose 6 mg daily , however patient may require high low initial dose recommend range 3 12 mg daily . The dose adjust point study , maximum dose 12mg/day . Flexible dose chosen best mimic actual clinical practice.The study duration split two phase . Phase A 12 week Phase B optional follow phase 40 week . Assessment efficacy safety perform Phase A baseline , 2 , 4 , 6 , 9 12 week Phase B 20 , 28 , 36 , 44 52 week . At first visit , full psychiatric history , demographic data physical examination undertaken . Throughout study , follow procedure , documentation evaluation perform : description concomitant medication ; hospitalisation psychiatric reason ; clinical deterioration ; Clinical Global Impression - Severity ( CGI-S ) Global Assessment Functioning ( GAF ) assessment ; Community Treatment Order ( CTO ) status ; weight ; adherence adverse event reporting . Physical examination perform periodically . Paliperidone ER OROS supply 3 mg , 6 mg , 9 mg tablet oral administration . In general , recommend Paliperidone ER dose 6 mg daily , however patient may require high low initial dose recommend range 3 12 mg daily . The dose adjust point study , maximum dose 12mg/day . The study duration split two phase . Phase A 12 week Phase B optional follow phase</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients must satisfy follow criterion eligible study : patient diagnose schizophrenia accord DSMIV criterion include newly diagnose patient Outpatients inpatient expect discharge within 8 week Patients legally acceptable representative must sign informed consent document indicate understand purpose procedure require study willing participate study . Patients meet follow criterion exclude participate study : patient resistant antipsychotic treatment Patients clozapine longacting injectable antipsychotic medication last 3 month Patients CGlS score &gt; 6 hospitalize longer 8 continuous week past 6 month Pregnant breastfeed females Patients history current symptom tardive dyskinesia neuroleptic malignant syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Treatment Outcome</keyword>
</DOC>